Zentalis Pharmaceuticals Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Julie Eastland
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully
Oct 03
Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher
Jun 19We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jun 13Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jul 02Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Mar 08Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jan 20CEO
Julie Eastland (60 yo)
no data
Tenure
Ms. Julie M. Eastland is CEO, President & Director of Zentalis Pharmaceuticals, Inc. from November 12, 2024. Ms. Eastland joined the Zentalis Pharmaceuticals, Inc. on November 12, 2024. She serves as Indep...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Legal Officer & Corporate Secretary | 2.3yrs | US$2.63m | 0.0097% $ 22.2k | |
| CEO, President & Director | no data | no data | no data | |
| VP of Finance & Interim Principal Accounting Officer | less than a year | no data | 0.048% $ 109.4k | |
| Chief Scientific Officer | less than a year | no data | 0.0035% $ 8.1k | |
| Chief Strategy Officer | 1.3yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
0.8yrs
Average Tenure
46.5yo
Average Age
Experienced Management: ZNTL's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | no data | no data | no data | |
| Chairman of the Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.2yrs | US$515.22k | 0.067% $ 154.9k | |
| Independent Director | 4.8yrs | US$617.78k | 0.20% $ 466.4k | |
| Director | less than a year | no data | no data | |
| Independent Director | 3.8yrs | US$516.97k | 0.054% $ 123.3k | |
| Independent Director | 6.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Board: ZNTL's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.